Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Oscar FernándezGuillermo IzquierdoVictoria FernándezLaura LeyvaVirginia ReyesMiguel GuerreroAntonio LeónCarlos ArnaizGuillermo NavarroMaria Dolores PáramoAntonio De la CuestaBernat SoriaAbdelkrim HmadchaDavid PozoRafael Fernandez-MontesinosMaria LealItziar OchotorenaPatricia GálvezMaria Angeles GenizFrancisco Javier BarónRosario MataCristina MedinaCarlos Caparrós-EscuderoAna CardesaNatividad Cuendenull null

Published in: PloS one (2018)

Infusion of autologous AdMSCs is safe and feasible in patients with SPMS. Larger studies and probably treatment at earlier phases would be needed to investigate the potential therapeutic benefit of this technique.

Keyphrases

multiple sclerosis
placebo controlled
mesenchymal stem cells
double blind
bone marrow
low dose
randomized controlled trial
clinical trial
study protocol
phase iii
stem cells
phase ii
open label
radiation therapy
umbilical cord
smoking cessation
locally advanced